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EDITORIAL
The ﬁrst clinical nuclear transplantation in
China: new information about a case reported
to ASRM in 2003
Before there was public debate on mitochondrial replace-
ment therapy (MRT) to treat mothers at risk of transmitting
mitochondrial disease (Hyslop et al., 2016), and before there
was a publicly traded company called OvaScience aiming to
use nuclear transplantation and stem-cell technologies to treat
infertility (Woods and Tilly, 2015), there was a solitary case
report from China about the use of nuclear transplantation
with donor oocyte-derived cytoplasm at the zygote stage to
overcome cleavage arrest in a patient’s embryos (Zhang et al.,
2003). The landmark abstract, presented to the 2003 annual
meeting of the American Society for Reproductive Medicine
(ASRM), was received with excitement and concern, senti-
ments that promptly seeped into the lay press. This was not
surprising considering the topic and the risk-sensitive audi-
ence of reproductive scientists listening to the presentation
given by the lead author, Dr John Zhang.
The case report described an IVF patient with normal fer-
tilization whose zygotes divided only once. Early develop-
ment arrest affected all the embryos of this patient in two
consecutive cycles. Approximately 10% of cleaving embryos
arrest in culture, but the repeated arrest of an entire cohort
is indeed rare, and, based on experimental evidence, could
be attributable to ooplasmic deﬁcits. Ooplasmic develop-
mental determinants are far from understood, but one
possibility is the deregulation of proteins like the stress sensor
p66Shc, which may affect signaling pathways for mitochon-
drial function (Betts and Madan, 2008). Complete develop-
mental arrest represents an extrememanifestation of ooplasm-
associated deﬁcits that can occur during human assisted
reproduction treatment cycles. The idea that ooplasmic deﬁ-
cits could be overcome by cytoplasmic replacement or aug-
mentation using donor oocytes or embryos is based on work
performed nearly three decades ago by Pratt and Muggleton-
Harris (1988) in the mouse. These authors injected 8 pl of cy-
toplasm extracted from normally dividing 2-cell mouse
embryos into single blastomeres of arrested 2-cell recipient
embryos. Using various combinations of blocking and non-
blocking mouse strains, 2-cell embryos were injected with the
aid of a membrane relaxant in order to avoid lysis. The authors’
aim was to study cell-cycle dependent blockage. They found
that only 4% of the total donor blastomere cytoplasmic volume
was sufﬁcient to overcome the block. The ability of a small
volume of presumably normal cytoplasm to change cell cycle
events in early embryos became the basis for cytoplasmic
transfer to treat oocytes of patients with multiple cycles of
abnormal embryo development, using ooplasm from donor eggs
during ICSI (Cohen et al., 1998). A similar approach has been
recently advocated using autologous transfer of mitochon-
dria derived from egg precursor cells (AUGMENT™,
OvaScience), which morphologically appear to resemble oo-
plasmic mitochondria (Woods and Tilly, 2015).
In a follow-up paper by Zhang and coworkers in this issue
of RBMOnline (Zhang et al., 2016) the case performed in China
in 2003 is presented in more detail. Why the 13-year hiatus
between presentation of the abstract at a meeting and pub-
lication of a full paper? Perhaps the authors were discour-
aged by the tragic loss of the resulting triplet pregnancy and
the criticism from colleagues and ethicists. Whatever the cir-
cumstances, the current paper describes the reconstitution
protocol and the DNA analyses which showed that the fetuses
had mitochondrial DNA from the oocyte donor and nuclear DNA
from the mother. Unfortunately, other details are missing:
no micrographs are provided of the nuclear transplantation
procedure and there is essentially no data or micrographs from
the two unsuccessful treatment attempts that led the authors
to apply nuclear transplantation in the ﬁrst place. None of
the patient’s zygotes were kept in culture as a control in par-
allel with the reconstituted zygotes in order to document re-
peated early arrest.
Other questions remain unanswered about this case. What
was the review and ethics approval process at Sun-Yat Sen
University where this experiment was conducted? Was the
demise of one fetus following premature rupture of mem-
branes at 24 weeks of gestation, and cord prolapse and demise
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of the last fetus at 29 weeks, related to the manipulations
or to the clinical management of this high-risk pregnancy?
Could the procedure be considered successful from a tech-
nical standpoint since the majority of the reconstructed
zygotes developed into apparently normal diploid embryos?
This was indeed an important, if limited ﬁnding, consider-
ing the developmental history. Are there details that may shed
more light on the technique itself and on whether this pro-
tocol differs signiﬁcantly from those used by teams advocat-
ing MRT in more recent studies (Hyslop et al., 2016; Tachibana
et al., 2013)?
These and other questions should add to the ongoing debate
and discussions in the literature and among legislative and
regulatory bodies such as the UK parliament, UK Human
Fertilisation and Embryology Authority (HFEA) and US Food
and Drug Administration (FDA) on the application of nuclear
transplantation technology for the purpose of preventing the
transfer of mitochondrial disease (Cohen et al., 2015;
Schandera and Mackey, 2016). The 2003 nuclear transfer pro-
cedure seems to be very similar to those proposed for MRT.
Is this experimental approach suitable for non-mitochondrial
disease applications? The recent Institute of Medicine (IOM)
report distinguishes between mitochondrial replacement
therapy and cytoplasmic replacement for overcoming infer-
tility (National Academies of Sciences, Engineering, and
Medicine, 2016). The HFEA seems to take a similar position,
inferring that cytoplasmic replacement should not be used for
treatment of infertility (Human Fertilisation and Embryology
Authority, 2015). It seems that the ethical debate has focused
on the risk factors. These were not discussed in depth in the
current paper.
Is it morally acceptable to carry out experimental proce-
dures such as nuclear transplantation or spindle transfer to
treat infertility patients? Medical ethics involve the presen-
tation of a moral standard to the practice of medicine. This
obviously implies the responsibility to ‘do no harm’, but also
to avoid increased risk, in both routine and experimental treat-
ments. This serious responsibility must always be balanced
with the valid search for treatment options providing signiﬁ-
cant potential beneﬁt even in the case of non-life threaten-
ing human disease like infertility. However, this could also
be argued in relation to MRT for mitochondrial disease, as the
egg, embryo and fetus do not exist prior to therapy and in
some cases there are alternatives like preimplantation genetic
diagnosis (PGD), egg donation or adoption, which could be con-
sidered. The suggestion that reducing the risk of transmit-
ting mitochondrial disease is not the moral equivalent of
overcoming infertility and that the latter requires a differ-
ent decision-making process or legal framework would beneﬁt
from further scrutiny. A parallel can be drawn with PGD where
testing for genetic mutations in embryos has been consid-
ered by many reproductive specialists as different to, and
somehow more justiﬁed than, testing for numeric chromo-
some anomalies. With reduced error and diagnosis-failure
rates, both applications seem to be more acceptable now and
the delineation between the two testing types is becoming
blurred. The same may be on the horizon for nuclear or cy-
toplasmic transfer.
Biotechnology, pharmacology and genetic diagnosis are
rapidly growing areas in China, but the presentation of guide-
lines regarding ethics and policy debates may be perceived
as not exhaustive by Western standards. This is not always
justiﬁed (Sipp and Pei, 2016). Modiﬁcation of the embryonic
genome may be allowed, but Chinese national guidelines have
prohibited the transfer of such embryos since 2003. There is
no national forum to which clinical experiments may be sub-
mitted for consideration, so examination of such proposals
remains the purview of local hospital ethics boards. Al-
though this is not unlike the familiar internal review board
(IRB) process, in the USA, for instance, other governmental
(e.g., the FDA) and non-governmental (e.g., NAS) forums rep-
resenting the public interest and including professionals in
diverse ﬁelds are also involved, debating the ethics of pro-
cedures such as cytoplasmic transfer, gene therapy,
xenotransplantation and MRT. Observers in the West may
wonder whether the clinical research climate in China en-
courages experimental approaches such as stem-cell thera-
pies, nuclear transplantation, and other developing
technologies without thorough discussion, but it is likely that
such deliberations do take place but are screened from public
view. In that context, it is not surprising that the ﬁrst clini-
cal applications of CRISPR-based technology for genome editing
are reported by Chinese teams employing the process in ab-
normal dispermic human zygotes (Kang et al., 2016; Liang
et al., 2015). The review process in 2003 of the case pre-
sented in this issue of RBMO may have been comparable with
the ethics approval process in the West in the 1970s and 1980s.
Views regarding fertilization and the status of the human
embryo seem less complicated in China than they are in the
West. In China, life is seen as a continuum, whereas in the
West, many argue that conception represents a sacredmoment
(life and its sanctity begin at conception). Perhaps the zygote
nuclear transplantation described by Zhang et al. should be
viewed from this perspective, although renewed criticism is
likely to follow given the experimental nature of this case,
missing data, and the prolonged period between initial an-
nouncement of the work and publication of this paper.
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